CHAMPIONS ONCOLOGY, INC. Deferred State and Local Income Tax Expense (Benefit)
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Deferred State and Local Income Tax Expense (Benefit) of $0 for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-07-27
- CHAMPIONS ONCOLOGY, INC. deferred state and local income tax expense (benefit) for fiscal 2026 was $0.00.
- CHAMPIONS ONCOLOGY, INC. deferred state and local income tax expense (benefit) for fiscal 2025 was $0.00.
- CHAMPIONS ONCOLOGY, INC. deferred state and local income tax expense (benefit) for fiscal 2016 was -$537.00K.
- CHAMPIONS ONCOLOGY, INC. deferred state and local income tax expense (benefit) for fiscal 2015 was -$287.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2026-04-30 | $0.00 10-K · filed 2026-07-27 | |
| 2025-04-30 | $0.00 10-K · filed 2026-07-27 | |
| 2016-04-30 | -$537.00K 10-K · filed 2016-07-29 | |
| 2015-04-30 | -$287.00K 10-K · filed 2016-07-29 | -$1.77M 10-K · filed 2015-07-29 |
| 2014-04-30 | -$148.00K 10-K · filed 2015-07-29 | |
| 2013-04-30 | -$196.00K 10-K · filed 2014-07-28 | |
| 2012-04-30 | -$172.00K 10-K · filed 2013-07-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |